Survival outcomes of adjuvant chemotherapy with modified weekly nab-paclitaxel and carboplatin for completely resected nonsmall cell lung cancer: FAST-nab

The relatively low toxicity profile of nab-paclitaxel plus carboplatin and its feasibility as an adjuvant administration was reported previously. This study aimed to evaluate the survival efficacy for completely resected patients with stage IB, II, and IIIA nonsmall cell lung cancer (NSCLC). Twenty-...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Anticancer Drugs
Autori principali: Marushima, Hideki, Kimura, Hiroyuki, Miyazawa, Tomoyuki, Sakai, Hiroki, Furuya, Naoki, Koji, Kojima, Nakamura, Haruhiko, Saji, Hisashi
Natura: Artigo
Lingua:Inglês
Pubblicazione: Lippincott Williams & Wilkins 2020
Soggetti:
Clinical Reports
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6964868/
https://ncbi.nlm.nih.gov/pubmed/31725045
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CAD.0000000000000857
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi